scientific advice EMA – Clinical Research Made Simple

Differences Between U.S. and EU Rare Disease Regulatory Pathways

August 18, 2025

Differences Between U.S. and EU Rare Disease Regulatory Pathways Comparing U.S. and EU Regulatory Pathways for Rare Disease Drug Approvals Introduction: Navigating Global Rare Disease Regulations Rare diseases pose significant challenges in clinical research, including small patient populations, limited natural history data, and high development costs. To encourage innovation, both the United States and European…

Rare and Orphan Disease Trials, Regulatory Frameworks

FDA vs EMA Incentives: A Comparative Review

August 7, 2025

digi

FDA vs EMA Incentives: A Comparative Review Comparing FDA and EMA Incentives for Rare Disease Drug Approvals Introduction: Why Incentives Matter in Rare Disease Drug Development Developing treatments for rare and ultra-rare diseases is often economically unviable without regulatory incentives. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have…

Rare and Orphan Disease Trials, Regulatory Incentives